The deal extends the interest-only period of the loan to November 2023 and reduces the minimum consolidated unencumbered liquid assets from $7,500,000 to $5,500,00, according to a June 30 news release.
Biolase also used a portion of proceeds from a recent equity offering to prepay $1,000,000 of the outstanding loan balance to the healthcare-focused investment firm.
Biolase recently entered a securities purchase agreement valued at $6.5 million with an unnamed institutional investor.
At the Becker's 5th Annual Future of Dentistry Roundtable, taking place November 12–14 in Chicago, dental leaders and executives will gain insights into emerging technologies, practice growth strategies and the evolving landscape of dental care delivery, with a focus on innovation, patient experience and operational excellence. Apply for complimentary registration now.
